Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Monotherapy in Metastatic Melanoma
NCT00139360Phase 2Completed
- Sponsor
- Haukeland University Hospital
- Start
- May 2005
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in melanoma, sponsored by Haukeland University Hospital. Primary endpoint: Clinical Response Rates at 10 years. Started May 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00139360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00139360.